Cubist Systematic Strategies LLC Acquires Shares of 175,083 Omnicell, Inc. (NASDAQ:OMCL)

Cubist Systematic Strategies LLC bought a new position in Omnicell, Inc. (NASDAQ:OMCL) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 175,083 shares of the company’s stock, valued at approximately $7,795,000. Cubist Systematic Strategies LLC owned about 0.38% of Omnicell as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in OMCL. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock worth $64,573,000 after acquiring an additional 699,925 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after purchasing an additional 394,820 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Omnicell by 32.9% during the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock worth $67,951,000 after purchasing an additional 377,883 shares during the last quarter. Oberweis Asset Management Inc. acquired a new stake in shares of Omnicell in the fourth quarter valued at $14,834,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Omnicell by 79.3% in the fourth quarter. Renaissance Technologies LLC now owns 456,343 shares of the company’s stock valued at $20,316,000 after buying an additional 201,831 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on OMCL. Wells Fargo & Company lowered their price objective on shares of Omnicell from $38.00 to $31.00 and set an “equal weight” rating for the company in a research report on Wednesday. Benchmark decreased their price objective on Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday, May 3rd. Finally, JPMorgan Chase & Co. decreased their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $45.83.

Omnicell Stock Performance

OMCL stock opened at $24.63 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a twelve month low of $22.66 and a twelve month high of $55.75. The business’s fifty day moving average is $32.76 and its 200-day moving average is $40.17. The company has a market cap of $1.15 billion, a P/E ratio of 91.23, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.10. The company had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.03 EPS. Equities research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.